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Abstract: The objective of this paper is to provide an overview of the recent developments 
in muscle physiology and biochemistry in general, and with respect to chronic obstructive 
pulmonary disease (COPD) specifically. As a way of illustration, we have presented data on 
the remodeling that occurs in vastus lateralis in two patients with COPD (COPD #1, forced 
expiratory volume in one second/forced vital capacity [FEV1/FVC] = 63%; COPD #2, FEV1/
FVC = 41%) exhibiting differences in muscle wasting as compared to healthy controls (CON; 
FEV1/FVC = 111 ± 2.2%, n = 4). Type I fibers percentages were lower in both COPD #1 (16.7) 
and COPD #2 (24.9) compared to CON (57.3 ± 5.2). Cross sectional area of the type I fibers of 
the patients ranged between 65%–68% of CON and for the type II subtypes (IIA, IIAX, IIX) 
between 74% and 89% (COPD #1) and 17%–32% (COPD #2). A lower number of capillary 
contacts were observed for all fiber types in COPD #1 but not COPD #2. Lower concentra-
tions of adenosine triphosphate (ATP) (24%–26%) and phosphocreatine (18%–20%), but not 
lactate occurred in COPD. In contrast to COPD #1, who displayed normal glucose transporter 
content, GLUT1 and GLUT4 were only 71% and 54%, respectively of CON in COPD #2. Lower 
monocarboxylate contents were found for MCT1 in both COPD #1 (63%) and COPD #2 (41%) 
and for MCT4 (78%) in COPD #1. Maximal oxidative enzyme activities (Vmax) for COPD #2 
ranged between 37% (succinic dehydrogenase) and 70% (cytochrome C oxidase) of CON. 
For the cytosolic enzymes, Vmax ranged between 89% (hexokinase) to 31% (pyruvate kinase) 
of CON. Depressions were also observed in Vmax of the Na+-K+-ATPase for COPD #1 (66% 
of CON) but not COPD #2 (92% of CON) while Vmax of the Ca2+-ATPase was near normal in 
COPD #1 (84% CON). It is concluded that disturbances can occur in muscle to a wide range 
of excitation, contraction and metabolic processes in COPD.
Keywords: vastus lateralis, fiber types, area, capillarization, metabolism, enzymatic pathways, 
excitation-contraction processes, glucose and monocarboxylate transporters
Introduction
It has become clear that the clinical management of patients with chronic obstructive 
pulmonary disease (COPD) in addition to treating the symptoms occurring as a direct 
result of the disease itself must also address some of the side effects of the disease. 
One side effect is the profound disability in exercise tolerance that occurs. It is now 
recognized that muscle dysfunction itself can be represent at least part of the etiology 
of the failure of COPD patients to perform many daily tasks of living.1,2
Efficient and effective therapeutic rehabilitation strategies depend on understand-
ing the mechanisms underlying the cause of the inability of the muscle to generate 
desired force responses. With this knowledge, dedicated protocols can be designed International Journal of General Medicine 2009:2 228
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Characterization of the potential of the muscle cell to 
perform contractile activity depends on an analysis of both 
of the excitation and contraction processes (E–C processes) 
in addition to the organization of the metabolic pathways that 
generate the energy for the E–C processes to perform their 
functions. Key elements in the E–C processes amenable to 
measurement in humans have typically involved the processes 
and proteins involved in cation cycling, namely the transport 
of Na+ and K+ across the sarcolemma and t-tubule and the 
uptake and release of Ca2+ by the sarcoplasmic reticulum 
(SR). The Na+-K+-ATPase and the SR Ca2+-ATPase are the 
critical enzymes involved in the active transport of these 
cations and consequently measurement of their properties 
is essential. Typically, in muscle homogenates, the measure-
ments include the catalytic activities of the enzymes involved, 
the protein and the isoform abundance. In the case of the SR, 
Ca2+-release and Ca2+-uptake can also be assessed.
Our studies appear to be among the first to examine 
selected properties in the vastus lateralis (VL) E–C processes 
in COPD. We have found that the maximal catalytic activities 
(Vmax) of both enzymes were depressed which occurred in 
association with alterations of the subunit isoforms.5,6
Although measurements of the catalytic activity of the 
myosin ATPase have not been reported in COPD, measure-
ments of the fiber types and subtypes have been published. 
It is well established that in COPD, the muscle contains a 
higher percentage of type II and a lower percentage of type I 
fibers,7 the magnitude of the change in fiber types dependent 
on disease severity.8,9 The determination of fiber types is 
based on the myosin isoforms and specifically the heavy chain 
isoforms which contain the ATPase.10 Interestingly, a well 
established effect of COPD is a reduction of muscle mass.11 
Given that the contractile proteins represent the majority of 
muscle protein, changes in one or more of the contractile 
proteins would be expected in COPD.
The primary function of the metabolic pathways is to 
supply the adenosine triphosphate (ATP) required by the 
ATPases to perform their unique functions. Consequently, 
it is possible that contractile failure may occur secondary to 
disturbances in energy homeostasis, mediated by deficiencies 
in metabolic pathway potential. The metabolic pathways and 
segments include high energy phosphate transfer, glycolysis, 
and oxidative phosphorylation.
The success of the metabolic pathways in responding 
to the demands for ATP, both at rest and during increased 
contractile activity, is based on the ability to protect phos-
phorylation potential12 which is determined primarily by the 
concentrations of ATP and PCr. Characterization of metabolic 
to improve specific outcomes, assuming that the disease 
does not prevent the appropriate cellular remodeling that 
is required. However, in general, clinical practice has not 
evolved to a state where specific functional deficits are 
identified and related to specific cellular abnormalities. 
There are several reasons for this, not the least of which is 
the incomplete knowledge of the recent advances that have 
been made in muscle physiology and biochemistry. Much 
progress has been made in the development of analytical 
protocols for the characterization of specific proteins and 
processes in the muscle cell and their role in mechanical 
behavior. Many of these properties can be assessed on 
relatively small amounts of tissue easily obtained by muscle 
biopsy. These techniques have been employed to determine 
the cellular abnormalities in a variety of disease states 
including COPD. However, in the case of COPD, relatively 
few studies have been published and as a result there is an 
inadequate understanding of the specific cellular alterations 
that occur in patients.2–4 Although it is recognized that in 
COPD the ability to generate an expected peak force and/or 
to engage to repetitive activity are compromised,2 studies 
have generally not measured the appropriate contractile 
properties responsible for these abnormalities.
In this review, we have several objectives. One major 
objective is to provide an overview, consistent with current 
knowledge, of the cellular processes regulating contractile 
behavior and the role of specific proteins and protein isoforms 
in mediating the functional properties of the processes. In 
addition, we summarize the literature on muscle and COPD, 
identifying areas where there is little or no published data. 
Finally, we provide information on specific analytical pro-
tocols that can be employed to provide a comprehensive 
assessment of muscle in COPD. To enhance clinical interest, 
we have supplemented the review with the results of two 
male COPD patients, differing in amount of lean body mass 
to illustrate via the detailed characterization performed, the 
differences in both the type and magnitude of the muscle 
abnormalities present.
It is well established that the loss of lean body mass 
(cachexia) frequently accompanying COPD compromises 
muscle force-generating potential as a result of fiber 
atrophy.2–4 Although the loss of muscle mass is undoubt-
edly important in the functional deficit that occurs, changes 
within the muscle fiber also appear important. In general, 
characterization of muscle in COPD has generally failed to 
address this aspect. In the following sections, a brief overview 
is provided of the relevant components involved with insight 
into the measurement of specific properties.International Journal of General Medicine 2009:2 229
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pathway potentials in muscle in COPD patients represent the 
most popular area of publication to date.
At the level of the organization of the metabolic path-
ways, it is commonly assumed that the potential for oxida-
tive phosphorylation has been compromised in COPD.2,3 
However, at least in the locomotor muscles, this assumption 
is based on the measurement of relatively few enzymes with 
reductions in the maximal activity of citrate synthase, an 
enzyme of the CAC, cited as primary evidence.13 Similarly, 
of the few studies which have concluded that the glycolytic 
potential is not affected in COPD, the same problem applies, 
namely the measurement of relatively few enzymes.14–16 
These assumptions are further compounded by the fact that 
not all studies in this area report similar effects of COPD.16,17 
In recent work from our group, in which we have measured a 
broad range of enzymes, we have found that both the poten-
tial for β-oxidation and oxidative phosphorylation (based on 
cytochrome oxidase) were depressed while the potential for 
glucose phosphorylation was increased.18
Since the flux rate in the metabolic pathways can also 
be limited by the availability of substrates such as CHO and 
accumulation of metabolic byproducts, it is important that 
measurement be made of the processes which control these 
properties. Glucose transport into the muscle, as an example, 
is facilitated by a family of glucose transporters (GLUT) 
of which GLUT1 and GLUT4 are primarily expressed in 
skeletal muscle.19 Similarly, the diffusion of the byproducts 
H+ and lactate is facilitated by monocarboxylate transporters 
(MCT) in which MCT1 and MCT4 predominate in skeletal 
muscle.20 In what appears to be the first study measuring these 
properties in skeletal muscle, we have found that the principal 
transporters, namely GLUT4 and MCT4, were depressed in 
the vastus lateralis of COPD patients.21
Histochemistry provides an opportunity to determine if 
the changes observed in muscle of COPD patients are spe-
cific to different fiber types. Curiously, relatively few studies 
have addressed this area and those that used histochemistry 
measured relatively few properties. An association between 
properties of the E–C-coupling processes and the potential 
of the metabolic pathways and segments in skeletal muscle 
of COPD patients would be expected. It is well established 
that the expression of these properties is correlated in the vari-
ous fiber types and subtypes.22 The most consistent finding 
published to date is that in the VL, COPD is accompanied by 
a decrease in type I and an increase in type II fiber percent-
ages.8 If the increase in type II fibers in COPD represents 
a simple transformation from type I fibers as proposed,2,3 it 
would be expected that the E–C-coupling processes would 
be altered accordingly, resulting in a more emphasized SR as 
an example. Similarly, the potential high-energy phosphate 
transfer and glycolysis should be increased and the oxidative 
potential decreased. Alternatively, if COPD acts directly on 
the E–C-coupling processes and the metabolic pathways, as 
suspected, possibly as a result of the accumulation of reactive 
oxygen species (ROS),23 reductions may occur regardless of 
the fiber-type shifts. Moreover; since cachexia is known to be 
prevalent in COPD, resulting in a loss of lean body mass,24 
it is possible that the areas of the different fiber types may 
be affected.
Histochemistry also provides the opportunity to assess 
the perfusion potential of the different fiber types. Given 
that the functional integrity of the metabolic pathways is 
also dependent on the supply of substrates such as O2 from 
the circulation, measurements of capillary density of the 
muscle fibers in conjunction with fiber areas is a desirable 
addition.25
In this review, for purposes of illustration, we have pro-
vided a comprehensive assessment of both the E–C-coupling 
processes and the metabolic pathways in COPD. We have 
concentrated on the muscle characteristics of two male 
patients differing in COPD severity and in cachexia severity 
on whom we had sufficient tissue from the VL to perform 
an extensive array of measurements using techniques modi-
fied for the measurement of properties on small amounts of 
tissue. Our guiding hypothesis was that in the COPD patients 
compared to healthy controls, a higher percentage of type II 
and a lower percentage of type I fibers would be observed 
in conjunction with a lower cross sectional area and lower 
capillarization of the fiber types. These differences would 
be accompanied by a lower oxidative potential and a higher 
potential for high-energy phosphate transfer and glycolysis. 
In addition, it is proposed that the catalytic potential of the 
Ca2+-ATPase as well a the capacity for Ca2+-uptake and Ca2+-
release would be higher in COPD. In contrast, the capacity for 
Na+-K+-ATPase activity would be lower in COPD compared 
to controls.
This work was part of a much larger project investigat-
ing skeletal muscle in COPD in which we have published a 
number of papers dealing with metabolic organization,18 the 
sarcoplasmic reticulum,5 the Na+-K+-ATPase,6 energetic and 
transporters status21 and muscle fiber type characteristics.26
Methods
Participants
In this report, we have selected two male patients with 
advanced COPD and compared the characteristics of the International Journal of General Medicine 2009:2 230
Green et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
vastus lateralis muscle with four healthy male control (CON) 
subjects. The two patients with COPD recruited from a list 
of patients who had participated in previous research studies 
at the Respiratoty Investigation Unit at Queen’s University 
(Canada). Healthy volunteers were recruited from the local 
community primarily by newspaper advertisements. Informed 
consent was obtained from all participants and ethics approval 
was obtained from the University and Hospital Health 
Sciences Human Research Ethics Board.
As can be observed in Table 1, the patients were both 
aged 66 years and weighed between 63.9 (COPD #1) and 
44.6 kg (COPD #2). Comparable values for CON were age, 
64.8 ± 3.6 years and 80.9 ± 8.3 kg, respectively. The body 
mass index (BMI; kg/m2) was 23.8 and 15.3 for COPD #1 
and COPD #2 which compared to 25.7 ± 2.1 for CON. The 
forced expiratory volume in one second/forced vital capacity 
(FEV1/FVC; %) ranged between 62.7 and 40.7 for the COPD 
patients compared to 111 ± 2.2 for CON. As expected, arterial 
O2 saturation (SaO2, %), diffusing capacity (DLCO, % pred) 
was depressed in both COPD #1 and COPD #2 compared 
to CON.
In terms of medication, COPD #1 was on Combivent 
(short-acting β2-agonist + short-acting anticholinergic), 
Advair (long-acting β2-agonist + inhaled corticosteroid) 
and Spiriva (long-acting anticholinergic). For COPD #2, 
the medications included Ventolin (short-acting β-agonist), 
Flovent (inhaled corticosteroid) and Atrovent. None of the 
CON subjects were on any of these medications. COPD #1 
had smoked for 47 pack-years, while COPD #2 had smoked 
for 45 pack-years. Both COPD patients were on supplemental 
O2, either continuously (COPD #2) or continuously during 
the day (COPD #1). Information describing the inclusion and 
exclusion criteria for both the COPD and CON volunteers 
have been reported previously.5,18
Peak oxygen consumption (  VO peak 2 ), measured during 
cycle ergometry, was 7.3, 5.7, and 30.5 ± 3.1 ml.kg-1.min for 
COPD #1, COPD #2 and CON, respectively (Table 1). For 
the COPD patients, these values were only 33% (COPD #1) 
and 20% (COPD #2) of predicted. Dynamic knee extension 
torque measured by computerized isokinetic dynameter 
(Cybex International, Medway, MA, USA) was also severely 
depressed in COPD with values of 39.8 and 19.2 Nm 
measured for COPD #1 and COPD #2, respectively. For 
CON, the maximal torque was 152 ± 16 Nm.
Additional details for test protocols appear in earlier 
papers.5,6,18,21
Tissue sampling
Tissue was obtained from the vastus lateralis on the 
dominant side using the needle biopsy technique.27 With 
this technique, the sampling site is identified (mid thigh), 
a small incision made after local freezing (lidocaine), and 
the tissue harvested using two to three separate biopsies. 
The biopsies were performed rapidly in succession, using 
fresh sterilized needles, by trained personnel. The needle 
containing the tissue from the first biopsy was rapidly 
plunged into liquid N2 and subsequently removed without 
thawing and stored at -80 °C until analyses. This tissue was 
used for the measurement of the substrate, glycogen and 
the labile high energy phosphagen compounds and related 
metabolites and the glycolytic intermediates. The tissue 
obtained from the additional biopsies was extracted from the 
needle, a section isolated and a homogenate prepared before 
freezing and storage at -80 °C. The remaining tissue was 
frozen in liquid N2 and stored at the same low temperature 
and a section prepared for histochemistry prior to freezing 
and storage.
Analytical protocols
The extensive array of properties was measured on different 
days during separate analytical sessions. For the measure-
ment of a given property, all samples, both CON and COPD, 
were assessed during the same analytical session.
Table 1 Anthropometric, pulmonary function and exercise 
characteristics of control and two patients with chronic obstruc-
tive pulmonary disease
Con COPD #1 COPD #2
Age (yr) 64.8 ± 3.6 66 66
weight (kg) 80.9 ± 8.3 63.9 44.6
Height (cm) 177 ± 1.5 164 171
Body mass index (kg/m2) 25.7 ± 2.1 23.8 15.3
Fev1 (L) 3.36 ± 9.2 0.49 0.54
Fev1 (% predicted) 110 ± 2.2 20 19
Fev1/FvC (%) 111 ± 2.2 62.7 40.7
DLco (% predicted) 124 ± 17 53.4 28.8
PaO2 (mmHg) 82.7 ± 1.2 NA 45.1
PaCo2 (mmHg) 43.7 ± 2.0 NA 46.6
SaO2 (%) 95.6 ± 0.26 92 82.2
vO2peak (ml.kg-1 min) 30.5 ± 3.1 7.3 5.7
Maximal torque (Nm) 152 ± 16 39.8 19.2
Notes:   values are x SE ± . For Con, n = 4.
Abbreviations: Con, control; COPD #1 and COPD #2, two chronic obstructive 
pulmonary disease patients; Fev1, forced expiratory volume in one second; FvC, 
forced vital capacity; DLco, diffusing capacity of the lung for carbon monoxide; PaO2, 
arterial oxygen tension; PaCo2, arterial carbon dioxide tension; SaO2, arterial oxygen 
saturation; v
.
O2peak, peak oxygen consumption during progressive exercise; maximal 
torque, maximal knee extention torque generated at 30° s; NA, not available.International Journal of General Medicine 2009:2 231
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The measurements performed included the labile 
metabolic compounds, a range of enzymes, GLUT and MCT 
isoforms, SR-related properties and the properties of the 
Na+-K+-ATPase (Table 2). These measurements were also 
complemented by the assessment of fiber-type related prop-
erties using histochemistry. Since all analytical techniques 
covering the properties assessed have been reported in detail 
in previous studies from this project, descriptions are kept 
to a minimum.
Histochemistry
We have used histochemistry to assess the distribution of the 
various fiber types and subtypes and to determine the cross-
sectional areas (CSA) and the number of capillaries in contact 
(CC) with fiber classification. These measurements were also 
complemented by determinations of both the maximal activity 
of succinate dehydrogenase (SDH) and the Ca2+-ATPase 
in fiber-specific types using microphotometric techniques. 
In brief, the histochemical procedures involved making serial 
slices of the muscle sample mounted in cross section in a 
cryostat (-20 °C) and measuring the specific properties in suc-
cessive sections. The first property assessed was the fiber type 
distribution using the procedures of Staron and colleagues,28 
which permitted identifying the distribution of type I, IC, IIC, 
IIA, IIAX, and IIX. Identification was based on the pH lability 
of the myofibrillar ATPase reaction,28,29 which is determined by 
the heavy chain isoform (HC) content, of which the ATPase 
is part of. For CON, an average of 216 ± 29 fibers were and 
for COPD #1 and COPD #2, the numbers were 150 and 213, 
respectively. Capillary contacts (CC) per fiber was permitted 
by using a lectin (ulex europaeus I) technique which allowed 
visualization of the capillaries.30 The activity of SDH was 
based on the determinations of the optical density (OD units) 
using the nitro blue tetrazolium as the reaction indicator.31 
Similarly, the SR Ca2+-ATPase activity was measured using 
similar microphotometric techniques according to the proce-
dures of van Der Laarse32 as modified in our laboratory.33 The 
OD was obtained using an image analysis system (Image-Pro; 
Media Cybernetics, Silver Spring, MD, USA). Where possible 
25 fibers of each type were assessed for these properties.
The fibers stained for SDH were also used to obtain the 
CSA of a similar number of fibers of each type, using a 
video monitor digitizing tablet. The CSA measurements in 
combination with the CC allowed calculation of the ratio of 
CC to CSA (µm2⋅10-3).
By using serial sections we were able to select a subgroup 
of specific fibers of each type and to measure all the proper-
ties in this sample of fibers.
Enzyme activities
To characterize the enzymatic pathways and segments we 
have measured the maximal activities (Vmax) of a wide range 
of enzymes which consisted of five from the mitochondria and 
five from the cytosol. The mitochondrial enzymes selected 
included three from the citric acid cycle (CAC), namely citrate 
synthase (CS), SDH, and malate dehydrogenase (MDH), one 
to represent β-oxidation, 3-hydroxyacyl-CoA dehydrogenase 
(HADH) and a complex of the electron transport system 
(ETC), cytochrome C oxidase (COX). The cytosolic enzymes 
were selected to represent glucose oxidation, hexokinase 
(HEX), glycogenolysis, phosphorylase (PHOSPH), glycolysis, 
phosphfructokinase (PFK), pyruvate kinase (PK), lactate dehy-
drogenase (LDH), high-energy phosphate transfer, and creatine 
phosphokinase (CPK). Multiple enzymes were selected from 
specific pathways to determine if they all responded in the same 
way with COPD. It has been assumed in studies investigating 
muscle in COPD that since the enzymes in a given pathway 
are in constant proportion to each other in the healthy subject,34 
that a single enzyme can be used to represent a pathway. This 
may not be so in unhealthy subjects.
With the exception of COX, all enzymes were measured 
fluorometrically at 24–25 °C in homogenates according to 
previously published procedures.35,36 With the exception of 
SDH and PFK, which were measured on fresh homogenates, 
prepared just prior to assay, all other enzymes were measured 
on homogenates that had been frozen after preparation. 
A spectrophotometric assay (30 °C) was used to measure 
COX which was based on the disappearance of reduced 
cytochrome C aborbance.
Enzyme activities were expressed per unit protein which 
was assessed by the use of the Lowry method as modified 
by Schacterle and Pollock.37 Samples from both CON and 
COPD for a given enzyme were measured in duplicate and 
during the same analytical session.
Metabolism
To evaluate the metabolic status of the muscle, the concen-
trations of the adenine nucleotides (ATP, ADP, and AMP) 
were measured by high-performance liquid chromatography 
(HPLC) as described previously,38 and the total adenine 
nucleotide pool (TAN) was calculated. Measurements of 
inosine monophosphate (IMP) was also measured with 
HPLC techniques. These properties were complemented 
by fluorometric-based measurements of glycogen, the 
glycolytic metabolites, pyruvate (Pyr) and lactate (Lac) and 
the high-energy compound, creatine phosphate (PCr) and its 
metabolite, creatine (Cr). The measurements of PCr and International Journal of General Medicine 2009:2 232
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Table 2 Summary of muscle characteristics studied in two patients with chronic obstructive pulmonary disease, techniques employed 
and properties assessed
Characteristic Patients Technique Properties
COPD #1 COPD #2
Fiber types
  Distribution * * Myofibrillar ATPase28,29 Fiber Types (%)
  Size * * Digitizing tablet53 Cross sectional area (µm2)
  Capillarization * * Lectin technique30 Number of capillaries (CC)
  Oxidative potential * * Microphotometry31 SDH activity (vmax)
  Cation transport * * Microphotometry32,33 Ca2+-ATPase activity (vmax)
Metabolic pathways (Vmax)
  CS, SDH, MDH * Fluorometric35,36 Citric acid cycle
  COX * Spectrophotometric18 electron transport system
  HADH * Fluorometric35,36 Fat oxidation
  HeX * Fluorometric35,36 Glucose oxidation
  PHOSPH * Fluorometric35,36 Glycogenolysis
  PFK, PK, LDH * Fluorometric35,36 Glycolysis




  ATP,   ADP,   AMP,  IMP,   TAN * * HPLC38 energy charge
  PCr, Cr, TCr * * Fluorometry21 energy charge
  Pyruvate, lactate * * Fluorometry21 Glycolytic metabolites
  Glycogen * * Fluorometry21 Carbohydrate substrate
Transporters (Content)
  GLUT1, GLUT4 * * electrophoresis/western blotting39 Glucose transport
  MCT1, MCT4 * * electrophoresis/western blotting39 Lactate transport
Cation transport
  Na+ -K+-ATPase
    vmax * * Spectrophotometric (3–0-MFPase)40,41 Maximal activity
  Content * * Scintillation (3H-Ouabain binding)42 enzyme content
  Ca2+-ATPase (Sr)
    vmax, Ca50, ηH * Spectrophotometric44,45 Maximal activity; 
Ca2+-sensitivity
  Ca2+-uptake * Spectrophotometric44,45 Ca2+-uptake
  Ca2+-release * Spectrophotometric44,45 Ca2+-release
Notes: The characteristics assessed included both the processes involved in the production of energy and the utilization of energy by the muscle cell. Metabolic status is a 
measure of the energetic state of the cell as assessed by the high-energy phosphate compounds. Metabolic pathway potential is based on the maximal activity (vmax) of repre-
sentative enzymes. For the transporter potential, the content of two isoforms of glucose and lactate were measured. For cation transport, the maximal activity (vmax) of both 
the enzymes involved in sarcolemma and t-tubule transport of Na+/K+ was measured (Na+-K+-ATPase) as well as the sarcoplasmic reticulum (Sr) Ca2+-uptake (Ca2+-ATPase). 
The Sr Ca2+-ATPase was also supplemented by measures of Ca2+-release and Ca2+-uptake. Selected fiber type characteristics were assessed by histochemistry. See Methods 
for further details.
Abbreviations: CS, citrate synthase; SDH, succinic dehydrogenase; MDH, malate dehydrogenase; COX, cytochrome c oxidase; HADH-3, hydroxyacyl-CoA dehydrogenase; 
HeX, hexokinase; PHOSPH, phosphorylase; PFK, phosphofructokinase; PK, pyruvate kinase; LDH, lactate dehydrogenase; CPK, creatine phosphokinase;   ATP, adenosine 
triphosphate;   ADP, adenosine diphosphate;   AMP, adenosine monophosphate; IMP, inosine monophosphate;   TAN, total adenine nucleotide; PCr, phosphocreatine; Cr, creatine; 
TCr, total creatine; GLUT1, glucose transporter isoform 1; GLUT4, glucose transporter isoform 4; MCT1, monocarboxylate transporter isoform 1; MCT4, monocarboxylate 
transporter 4; Ca50, calcium concentration necessary to elicit 50%   vmax; nH, Hill coefficient obtained by using the relationship between Ca2+ concentration and Ca2+-ATPase 
activity; Sr, sarcoplasmic reticulum.
Cr enabled total creatine (TCr) to be determined. We have 
also estimated the concentration of both free ADP (ADPf) 
and free AMP (AMPf) which is based on the near-equilibrium 
properties of the CPK and adenylate kinase reactions. 
Details including the constants and assumed concentrations 
and regression equation appear in an earlier publication.21 
It should be noted that given the labile nature of the measured 
metabolites that extraction occurred on freeze-dried tissue. 
All properties were performed in duplicate and expressed 
per unit dry weight tissue.International Journal of General Medicine 2009:2 233
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Transporters
The transporters measured were for glucose, GLUT1 and 
GLUT4, and for the monocarboxylates, MCT1 and MCT4. 
All transporters were assessed using electrophoresis and 
Western blotting techniques as described previously.39 
Isoform detection was performed with an enhanced che-
miluminescence procedure and the blots analyzed with a 
bioimaging system. For GLUT1 and GLUT4, the anti-GLUT 
polyclonal antisera was CBL242 and CB243, respectively, 
obtained from Chemicon International (Temecula, CA, 
USA). For MCT1 and MCT4, the antisera was AB3538P and 
AB3316P, respectively diluted 1:400 and also obtained from 
Chemicon International. All samples were run in duplicate on 
separate gels with CON and COPD samples matched. Protein 
was measured by Bio-Rad assay (Bio-Rad Laboratories, Her-
cules, CA, USA). Values for COPD were calculated relative 
to CON which was set at 100%. The values were expressed 
relative to α-actin content (used to match for protein loading) 
and normalized to CON values.
Na+-K+-ATPase
Two properties were measured for this enzyme, namely the 
maximal catalytic activity (Vmax) and the maximal content 
(βmax). The determination of Vmax is based on the use of an 
artificial substrate, namely 3-O-methylfluorsecein phosphate 
(3-O-MFP) which is used as a substitute for the aspartylphos-
phate intermediate of the enzyme.40 The catalytic activity is, 
in effect, determined as the measurement of the K+-stimulated 
3-O-methylfluorescein phosphatase (3-O-MFP-ase), based on 
an assay originally developed by Nørgaard and colleagues40 
and subsequently modified to produce a clear Vmax.41 Enzyme 
activity, using the average of three trials, was based on the 
slope of the reaction before and after the addition of KCl using 
fluorescence spectroscopy. Protein content of the samples was 
based on previously established techniques.37
For the measurement of enzyme content (βmax), the 
vanadate-facilitated [3H] ouabain binding technique was 
used.42 A complete description of this assay, including 
details of the incubation buffer, corrections employed and 
procedural details appear in earlier publications.43 This assay 
was conducted on two tissue samples, each weighing between 
2 and 8 mg, and βmax expressed per unit wet weight.
Sr properties
To characterize the SR, we have measured the catalytic proper-
ties of the Ca2+-ATPase, namely the maximal activity (Vmax), 
the free Ca2+ [Ca2+
f] needed to elicit 50% Vmax (Ca50), and the 
Hill coefficient (nH), defined as the slope of the relationship 
between Ca2+-ATPase activity and [Ca2+]f. These measurements 
were also supplemented by determinations of Ca2+-uptake and 
Ca2+-release. By measuring Vmax, with and without the Ca2+-
ionophore, A-23187, we were able to calculate the ionophore 
ratio which provides an indirect measure of the integrity of the 
SR membrane for Ca2+.44 The coupling ratio, determined by the 
ratio of Ca2-uptake to Vmax, provides an index of the energetic 
efficiency of Ca2+-sequestration into the SR.44
Enzyme activity was measured at 37 °C using a 
spectrophotometric method44 as modified by our group.45 
In this assay, the Ca2+-dependent activity of the enzyme is 
obtained by subtracting the Ca2+-independent activity or basal 
activity. The basal activity is obtained using cyclopiazonic 
acid, which completely inhibits the Ca2+-ATPase activity.46 
The Ca2+-uptake and Ca2+-release was measured during the 
same assay as described.45 With our protocol, we observed 
two phases of Ca2+-release which we labeled phase I and 
phase II.45 Phase I represents the initial fast phase of release 
while phase II is a slower more delayed phase.45 It should be 
noted that, unlike the Ca2+-ATPase which can be measured 
on frozen tissue with minimal loss of activity, Ca2+-uptake 
and Ca2+-release must be measured on homogenates prepared 
on fresh tissue which can then be stored.
To measure the level of [Ca2+]f, which these assays 
depend on, dual-wavelength spectrofluorometry and the 
Ca2+-fluorescent dye, indo-1 was employed. Additional details 
appear in earlier publications from our laboratory.45 Where 
possible all measurements were performed in duplicate 
and care was taken to ensure that CON and COPD samples 
were matched in a given analytical session. As in previous 
measurements, the values were expressed per unit protein 
with protein assessed as described.37
Results
Histochemistry
Clear differences were observed in the distribution of the fiber 
types and subtypes between the healthy, control participants 
and the two COPD patients (Table 3). The COPD patients 
displayed a pronounced lower percentage of type I fibers. The 
increase in the type II fiber percentage observed in COPD 
was distributed in both the type IIA and the type IIAX for 
both patients. Type IIX fibers were noted to be elevated in 
COPD #1 but not COPD #2. The percent of the type IC and 
type IIC only ranged between 0.5% to 3% in CON. Type IC 
fibers was observed to increase to 6.7% in COPD #1 while 
no type IIC fibers were detected in COPD #2.
Differences were also noted between the healthy 
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types (Figure 1). In the case of the type I fibers, the 
area was between 35% to 38% lower in COPD. For the 
type II fiber types, clear differences existed between 
the COPD patients. For COPD #1, areas ranged between 
89% (IIA), 83% (IIAX), to 74% (IIX) of CON. Such was 
note the case for COPD #2 where the areas were only 17% 
(IIA) and 32% (11AX and IIX) of CON. The capillary 
counts also suggested a heterogenous response between the 
COPD patients. In general, the capillary counts were better 
protected in COPD #2 compared to COPD #1. Compared to 
CON, the capillary counts in type I were lower by 59% and 
increased by 28% in COPD #1 and COPD #2, respectively. 
For the type II subtypes, comparative reductions were 56% 
and 30% for IIA, 39% and 0% for IIAX, and 68% and 9% 
for IIX in COPD #1 and COPD #2, respectively.
A contrasting profile also existed for the capillary-to-fiber 
area ratio properties in the two COPD volunteers. For 
COPD #1, the ratio was lower than CON regardless of fiber 
type, with observed differences of 61%, 48%, 72%, and 41% 
observed for I, IIA, IIAX, and IIX, respectively. In contrast, 
for COPD #2, the capillary-to-fiber area ratio was 1.8-, 4-, 
3.2-, and 2.8-fold higher of CON for I, IIA, IIAX, and IIX, 
respectively as a result of the severe atrophy that occured.
We have also measured the activity of SDH and the 
Ca2+-ATPase in fiber-specific types of CON and COPD 
(Table 3). In general, SDH activity was not substantially 
different between the COPD individuals and the CON. For 
COPD #2, there was a trend for the activities to be higher 
in most fiber types as indicated by the approximately 20% 
to 23% higher activity observed in the type I, IIA, and IIAX 
fibers. In contrast to SDH activity, Ca2+-ATPase2+ activity 
was clearly depressed in COPD #2 compared to CON, the 
magnitude of the decrease depending on the fiber type 
(Table 3). For this patient, the decrease observed was most 
pronounced for the type I and type IIA fibers, representing 
30% and 52% of CON, respectively. For the type IIAX and 




The relative levels of GLUT1 and GLUT4 were well 
protected in COPD #1, but not in COPD #2 (Figure 2). 
In COPD #2, GLUT1 and GLUT4 were 71% and 54% of 
CON, respectively. In contrast to the GLUT in COPD #1, 
both MCT1 and MCT4 were subnormal which in the case of 
MCT1 was 37% and in the case of MCT4 was 22%. A 59% 
lower MCT1 content was also observed for COPD #2. 
Unfortunately, no values are available for MCT4 for this 
patient.
enzymes
Both the mitochondrial and the cytosolic enzyme 
activities were all lower in COPD #2 compared to CON 
(Figures 3A, 3B). For the enzymes of the CAC, CS, SDH, 
and MDH were reduced by 47%, 63%, and 49%, respectively. 
Table 3 Selected histochemical properties in tissue obtained from the vastus lateralis muscle of two patients with chronic obstructive 
pulmonary disease and healthy controls
Fiber type
I IC IIC IIA IIAX IIX
Distribution (%)
  CON 57.3 ± 5.2 0.50 ± 0.23 3.0 ± 2.4 27.9 ± 0.44 3.1 ± 1.7 8.2 ± 4.3
  COPD #1 16.7 6.7 2.7 37.3 11.3 25.3
  COPD #2 24.9 0.5 0.0 49.3 17.8 7.5
SDH (OD units)
  CON 0.16 ± 0.02 0.14 ± 0.04 0.15 ± 0.05 0.14 ± 0.03
  COPD #1 0.18 0.16 0.14 0.12
  COPD #2 0.21 0.17 0.18 0.13
Ca2+-ATPase (OD units)
  CON 0.10 ± 0.02 0.31 ± 0.04 0.29 ± 0.04 0.36 ± 0.07
  COPD #1 0.13 0.30 0.30 0.37
  COPD #2 0.07 0.15 0.24 0.33
Notes: values are x SE ± . For CON, n = 4.
Abbreviations: CON, control; COPD #1 and COPD #2, two chronic obstructive lung disease patients. Distribution, % distribution of different fiber types; SDH, succinic 
dehydrogenase activity; Ca2+-ATPase, Ca2+-ATPase activity.International Journal of General Medicine 2009:2 235
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Substrate and metabolites
COPD was accompanied by reductions in phosphorylation 
potential as indicated by the lower concentrations of the 
high-energy phosphagen compounds (Table 4). For ATP, the 
reductions ranged between 22% to 24% for the two patients 
while reductions in TAN ranged between 17% and 22% in the 
COPD patients. For COPD #2, there was an approximately 
threefold higher IMP concentration than CON. For COPD #1, 
IMP appeared normal. Comparable reductions of between 
17% and 20% in the COPD participants were observed for 
PCr (Table 4). Only in COPD #2 was there a suggestion 
that TCr was reduced (13%) as well. Overall phosphoryla-
tion potential was 80% and 83% of CON for COPD #1 and 
COPD #2, respectively. With regards to the endogenous 
carbohydrate substrate, glycogen, COPD #1 appeared able 
to maintain and even increase (19%) storage while COPD #2 
showed a substantial reduction (24%). Lactate concentration 
was within a normal range for both patients.
Cation cycling
Measurements were performed on the Na+-K+-ATPase for 
determinations of maximal activity (Vmax) and maximal 
content (βmax) (Table 5). For Vmax, a reduction of 34% was 
observed in COPD #1 while the Vmax for COPD #2 was the 
normal range (92%). Both patients displayed changes in βmax 
with COPD #1 and COPD #2 with values approximately 
20% lower and higher, respectively.
For Ca2+-ATPase, Vmax was modestly lower (16%) as was 
the Ca2+-uptake (14%) for COPD #1 (Table 5). Interestingly, 
for this patient differences were clearly evident in the Ca2+-
sensitivity of the enzyme with Ca50 and ηH being higher and 
lower, respectively in the disease state. Only small differ-
ences (9%) observed in the ionophore ratio and no difference 
in the coupling ratio. There was a suggestion of a reduced 
Ca2+-uptake for phase I (18%) but not phase II (5%).
Discussion
In this study, our primary aim was to provide a current review 
of the advances that have occurred in muscle physiology and 
biochemistry, both with regards to the proteins and processes 
regulating contractile function and the analytical techniques 
available for measurement. To highlight clinical relevance, we 
have provided the most comprehensive and integrated pro-
file of a wide range of muscle properties ever performed on 
COPD patients. To contrast the different effects of COPD on 
muscle, we have selected two COPD patients with advanced 
COPD disease but differing in the degree of cachexia. Dual 
energy X-ray (DEXA) to measure body composition26 was 






























































































Figure 1 Fiber-specific histochemical properties in tissue obtained from vastus lateralis 
muscle in healthy volunteers and two patients with advanced chronic obstructive 
pulmonary disease.
Notes: For CON, values are means ± Se (n = 4).
Abbreviations: CON, control; COPD #1 and COPD #2, two chronic obstructive pul-
monary disease patients; I, IIA, IIAX, IIX, fiber types and subtypes; CSA, cross-sectional 
area; capillary counts, number of capillaries ± around a fiber; capillary contacts/CSA, 
number of capillaries around a fiber divided by the CSA; SE, standard error.
This compared to a 30% lower activity for COX, the ETC 
complex measured. For the cytosolic enzymes, the greatest 
reduction in activity was observed for PHOS (63%) and 
PK (69%) followed by PFK (31%), CPK (32%), LDH 
(17%), and HEX (11%). Protein concentration (mg/g) was 
206 ± 4.9 for CON and 153 for COPD #2, a difference of 
26%. No tissue was available for the enzyme measurements 
in COPD #1.International Journal of General Medicine 2009:2 236
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applied to confirm differences between COPD #1 and COPD 
#2 in lean body mass. Our objective was to address both the 
processes involved in ATP production (metabolic pathways) 
and the processes involved in ATP utilization with emphasis 
on cation cycling.
To-date, studies designed to identify the underlying 
mechanisms involved in muscle weakness and fatigue so 
prevalent in COPD have almost exclusively concluded that 
disproportionate increases in lactate during contractile activity 
is due, at least in part, to deficiencies in oxidative potential. 
In general, these conclusions have been based on the lower 
Vmax of a single enzyme of the CAC. It is our hypothesis, that 
identification of mechanisms for muscle mechanical failure 
and abnormal metabolic response must include a broader 
range of measurements, including those involved in cation 
cycling and substrate and metabolic by-product transport. 
Our findings using two patients clearly indicate that this is 
the case. A critical issue relates to the mechanisms underlying 
the different phenotype observed in the vastus lateralis in the 
COPD patients. Such mechanisms must be able to account 
both for the properties that are common to both patients and the 
properties that were differentially expressed. In the following 
sections, we categorize and review the properties affected.
Histochemistry
A common and expected response was the large increase 
in the percentage of the fast-twitch, type II fibers and the 
decrease in the slow-twitch, type I fiber percent observed in 
both patients in this study and our earlier study.26 The change 
in the fiber type profile in COPD which has been observed 
many times previously2,4 has been attributed to a simple 
transformation of fiber types.3 Since the histochemical iden-
tification of the different fiber types is based on the myosin 
heavy chain isoforms,48 the shift would have to involve both 
the isolated expression of a single isoform, namely HCIIA or 
HCIIX in the case of the IIA and IIX fibers, respectively or the 
co-expression of more than one isoform such as IIA and IIX 
in hybrid fibers (IIAX). In addition, the expression of the 
HCI isoform would have to be either partially (IC, IIC) or 
completely inhibited (IIA, IIX, IIAX). Although, such a 
transformation is possible particularly in conditions such as 
spinal cord injury,49 it has not been observed, at least to a com-
parable extent, in physiological settings, involving profound 
reductions in contractile activity50 or hypoxic environments.51 
Another possible explanation to account for the alteration in 
fiber type distribution in COPD is a selective apoptosis of the 
type I fiber pool. There is increasing evidence to indicate that 
apoptosis does occur, particularly in severe COPD23 and that 
the type I fibers may be selectively targeted.23 However, in 
multinucleated cells such as the myocyte, apoptosis appears 
to induce only atrophy.23
Atrophy was pronounced in the type I fibers in both 
patients to a similar degree. However, only in COPD #2 was 
a predominant atrophy found in the type II fiber subtypes. 
This patient also had the lowest body weight and BMI, 
which appears to be primarily determined by the atrophy that 
occurs.2 Muscle atrophy has also been reported in previous 
studies, however the fiber population affected appears in 
dispute since one study has reported only a selected effect 
on the less oxidative type II subtypes (IIAX and IIX)52 while 
another study has found that the type I and the more oxida-
tive fibers (IIA and IIAX) are selectively affected.53 Our 
study suggests that the fiber-type specific pool affected may 
depend on the amount of muscle wasting that occurs. It is 
also possible that the effect on specific fiber types may be 
affected by gender.26
It is clear that increased capillarization of the muscle 
fiber was not an adaptive response to advanced COPD since 
no increase in the number of capillaries was observed in 
either patient. Muscle wasting was related to a protective 
effect since COPD #2 who had the lowest BMI, with the 
exception of type IIA, maintained a normal number of cap-
illaries per fiber while COPD #1, the patient with a normal 
BMI, displayed a pronounced reduction in capillaries in all 
fiber types and subtypes. The results observed for COPD 
#2 are generally consistent with an earlier study which also 
reported lower capillarity in the different fiber pools.53 The 
ratio of the CC per unit CSA, a structural index of perfusion 



















Figure 2 relative contents of glucose and monocarboxylate transporters in healthy 
volunteers and two patients with advanced chronic obstructive pulmonary disease.
Notes: For CON, values are means ± Se.
Abreviations: % Standard, percent change first calculated against a standard and 
then calculated as a relative change from 100% (CON); GLUT1 and GLUT4, glucose 
transporter isoforms, GLUT1 and GLUT4, respectively; MCT1 and MCT4, monocar-
boxylate isoforms, MCT1 and MCT4, respectively; Se, standard error.International Journal of General Medicine 2009:2 237
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potential,25 was compromised in COPD #1 and increased in 
COPD #2 by primarily different mechanisms. In COPD #1, 
the increase was mediated primarily by the disproportionate 
reductions in the number of capillaries while in COPD #2, the 
improved response occurred basically as a result of the more 
pronounced reduction in CSA. The latter response is typical 
to that observed during altitude acclimatization where fiber 
atrophy is present without changes in angiogenesis.51
Biochemistry
The most common defect observed in the muscle of COPD 
patients is a lower activity of CS13,14,16,54 and in isolated stud-
ies, SDH,16 which has been used to support a diagnosis of a 
reduced potential for oxidative phosphorylation.3 Moreover, 
not all studies have reported reductions in CS with COPD.55 
For COPD #2, the patient with the low BMI, it is clear that 
not only is CS reduced, but the reduction extends to all of 
the other CAC and ETS enzymes and complexes studied. 
Moreover, unlike earlier studies which have not reported 
differences between the healthy and COPD groups in the 
limited number of cytosolic enzyme activities,14,54 we found 
that in this patient the regulatory enzymes of glycogenolysis 
and glycolysis, namely PHOS and PFK, were substantially 
lower. However, the reductions did not extend to all cytosolic 
enzymes since HEX and LDH were normal, indicating a 
preserved capacity for glucose phosphorylation and lactate 
oxidation. These differences contradict an earlier study which 
has found elevations in PFK and possibly LDH in patients 
with severe COPD.16 Interestingly in this study, BMI was 
protected. The protection of muscle mass and fiber CSA 
may be important in the changes observed in the cytosolic 
enzymes since many are bound to the myofibrillar proteins,56 
which undergo the degradation. Unfortunately, the lack of tis-
sue prevented enzyme measurements in COPD #1. Given the 
fact that the activity of SDH, measured microphotometry, was 
normal in this patient, it is possible that oxidative potential 
was not compromised. In a related study from this project, 
among the mitochondrial and cytosolic enzymes examined, 
alterations in Vmax in only COX and HADH (reductions) and 
HEX (increase) were observed in moderate to severe COPD 
patients.18 It appears that multiple factors, including disease 
severity, may alter the individual enzyme response and the 
potential of the metabolic pathways and segments.
A unique feature of the current study was the measure-
ment of the glucose and monocarboxylate transporters, only 
previously measured in muscle of COPD patients in a recent 
study from our group.21 In this earlier study, we have reported 
that GLUT4 and MCT4 were depressed while GLUT1 and 
MCT1 were normal. These results indicate that abnormali-
ties in the content of the transporters may also contribute to 
the disturbances in the metabolic responses to contractile 
activity. In COPD #2, the patient with the low BMI, the 
ability to transport glucose across the cell membrane, both 
during exercise and recovery, would be expected to be 
compromised given the much lower content of GLUT1 and 
GLUT4.19 Moreover, the reduced level of MCT1, the minor 
isoform primarily involved in facilitating lactate into the cell57 
would be expected to impair the distribution of lactate and H+ 
to other tissues. No measurements are available for MCT4, 
the principal isoform, which functions to transport lactate 
and H+ out of the cell where it is generated.57 In COPD #1, 
both MCT1 and MCT4 were depressed with the greatest 
reduction observed for MCT1. In this patient, the potential 
for glucose transport was unaffected, given the normal levels 
of both GLUT1 and GLUT4.
Figure 3 Maximal activities of mitochondrial A) and cytosolic B) enzymes in vastus 
lateralis muscle of healthy volunteers and a patient with advanced chronic obstruc-
tive pulmonary disease.
Notes: For CON, values are means ± Se (n = 4).
Abbreviations: CON, control; COPD #2, patient with chronic obstructive pul-
monary disease. vmax, maximal enzymatic activity; CS, citrate synthase; SDH, succinic 
dehydrogenase; MDH, malate dehydrogenase; COX, cytochrome c oxidase; HADH, 
3-hydroxyacyl-CoA dehydrogenase; HeX, hexokinase; PHOS, phosphorylase; PFK, 
phosphofructokinase; PK, pyruvate kinase; LDH, lactate dehydrogenase; CPK, creatine 
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It is apparent that even with the depression in both the 
glucose and monocarboxylate transporters in COPD #2, 
glycogen and lactate concentrations in resting muscle were 
only modestly reduced (glycogen) or unaffected (lactate). 
In COPD #2, a modest supercompensation in glycogen 
was observed accompanied by modest elevations in resting 
lactate. It is emphasized that the transporters represent but 
one among many factors governing regulation.19,20
Since muscle contractility is intimately dependent on the 
viability of the E–C coupling processes, we have also mea-
sured several properties regulating cation exchange across 
the sarcolemma and t-tubule and the SR. The Vmax of the 
Na+-K+-ATPase, which regulates the active transport of Na+ 
and K+, was normal in COPD #2 and reduced in COPD #1. 
The lower Vmax in COPD #1 could be explained by the lower 
Na+-K+-ATPase content. The reason for the different response 
pattern between the patients is not clear. However, the greater 
atrophy observed in the type fiber subtypes in COPD #2 may 
have some influence. Since this cation pump is distributed 
in both in the sarcolemma and t-tubule and the cytosol,58 the 
greater loss of myofibrillar protein with atrophy could result 
in an apparent increase in pump concentration since we have 
expressed our results relative to total protein content. Chronic 
hypoxia is known to depress the content of the pump59 which 
could be important given the arterial hypoxemia that exists 
in COPD. However, this would not appear to explain the 
different responses observed since the patients were gener-
ally comparable in pulmonary function. The lower catalytic 
activity of the Na+-K+-ATPase observed in COPD #1 may 
provide a rationale for the impaired membrane excitability 
previously shown to occur in COPD.60 Moderate to severe 
COPD also is accompanied by a reduction in muscle Vmax, 
due possibly to isoform shifts since the content of enzyme 
was unchanged.6
We have reported that disturbances in SR calcium cycling 
in muscle may accompany COPD given the depression in 
Ca2+-uptake observed which appears to be mediated by the 
lower Vmax of the Ca2+-ATPase.5 The reduction in Ca2+-uptake 
was not accompanied by disturbances in the two phases of 
Ca2+-release. Perhaps of greater significance than the modest 
reductions in Ca2+-uptake observed was the changes that 
occurred in the Ca2+-sensitivity of the enzyme.5 The reduction 
in Ca2+-sensitivity, as indicated by both the Ca50 and the ηH, 
could have important functional implications since to obtain a 
given catalytic activity and consequently a given Ca2+-uptake, 
elevations in Ca2+ or changes in second messenger regulation 
would appear necessary.61 The change in the Ca2+-sensitivity 
of the enzyme suggests that structural alterations may have 
occurred to the enzyme61,62 and/ or alterations in regulatory 
behavior.47 Membrane integrity and the efficiency of Ca2+-
cycling, as measured by the ionophore ratio and coupling 
ratio were normal. Essentially, the same changes in the SR 
occurred in COPD #1. In COPD #2, no biochemical mea-
surements of the SR were possible. However, based on the 
microphotometric assessments, a pronounced depression in 
Vmax of the enzyme is clearly indicated based on the lower 
activity measured, particularly in the type I and type IIA 
fibers. It is possible that the depression in the Ca2-ATPase 
may be even more depressed in COPD #2 than COPD #1 
since an earlier report has found that the severity is related to 
a lower BMI.63 Since precise regulation in Ca2+
f is important 
in defending against fatigue during contractile activity,64 it is 
conceivable that the SR could be implicated in the failure of 
muscle in COPD patients to function normally.
A critical condition in the ability of muscle to maintain 
normal function is the protection of energy homeostasis. 
Maintenance of normal muscle energy levels is particularly 
challenging in COPD where oxygen availability to the 
muscle cell may be compromised.12 Energy homeostasis 
is dependent in part, on the phosphorylation potential, 
represented as the sum of the concentrations of the adenine 
nucleotides and the phosphocreatine. Both COPD patients 
displayed an inability to maintain a normal phosphorylation 
Table 4 The concentration of high-energy phosphates and 
metabolites, glycogen and lactate in vastus lateralis muscle of 
healthy control subjects and two patients with chronic obstructive 
pulmonary disease
CON COPD #1 COPD #2
Glycogen  
(mmol (glucose/units. kg -1.d.w))
261 ± 26 310 198
ATP (mmol. kg-1d.w.) 22.1 ± 0.54 17.3 16.9
ADP 3.34 ± 0.19 2.60 4.32
AMP 0.08 ± 0.01 0.034 0.156
TAN 25.5 ± 0.71 19.9 21.3
IMP 0.10 ± 0.03 0.07 0.32
PCr 83.8 ± 4.1 66.9 69.0
Cr 49.6 ± 2.5 60.2 46.2
TCr 133 ± 1.8 127 115
PP 109 ± 3.6 86.8 90.3
Lactate 1.5 ± 0.05 2.0 1.5
Notes: values are x SE ± . For CON, n = 4.   with the exception of glycogen, the units 
for all properties are mmol. kg-1 d.w.
Abbreviations: CON, control; COPD #1 and COPD #2, two chronic obstruc-
tive lung disease patients; ADP, adenosine diphosphate; AMP, adenosine monophate; 
TAN, total adenine nucleotide; IMP, inosine monophosphate; PCr, phosphocreatine; 
Cr, creatine; TC, total creatine; PP, phosphorylation potential.International Journal of General Medicine 2009:2 239
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potential, a finding that we have reported previously in 
patients with moderate to severe COPD.21 The pool size of 
both the adenine nucleotides and total creatine were reduced, 
possibly as a consequence of the degradation to IMP and 
inosine with subsequent loss from the cell.65 A similar 
response has been previously reported in COPD.66,67 Given 
the relatively low ATP demands that occur in muscle at 
rest, it is curious that normal phosphorylation potentials 
cannot be maintained. It has been suggested that the pri-
mary problem occurs a result of mitochondrial dysfunction 
which results in a reduction in the P/O ratios and loss of 
efficiency.23 The reserves of the endogenous substrate, 
glycogen, would appear not to be a factor since glycogen 
was within the normal ranges in both patients.
Perspectives and significance
In summary, in this paper we have provided an overview 
of the current state of knowledge on the factors regulating 
contractile behavior in the muscle cell. We also provide a 
brief review of what is known regarding the abnormalities 
that occur in muscle in COPD, an area that merits deeper 
investigation, given the weakness and fatigue that accom-
panies COPD. To promote clinical interest, we present the 
results obtained from two case studies in which an extensive 
profile of muscle properties was obtained. As a practical 
benefit, aimed at facilitating the inclusion of muscle-based 
assessment into clinical practice, we provide information on 
tissue sampling and on the analytical techniques employed 
for the measurement of specific properties. It is emphasized 
that the results of the two case studies are for purposes of 
illustration only. Conclusions regarding the type and mag-
nitude of specific muscle abnormalities, both with regard to 
disease severity and associated side effects, such as cachexia, 
depend on the completion of many more studies with much 
larger sample sizes. It is also emphasized that given the 
limited amount of tissue available, some of the analytical 
profiles completed within each of the muscle characteristics 
addressed is by necessity incomplete. Regardless, based on 
the measurements completed, it is inviting to speculate on the 
potential implications of the abnormalities that were observed 
in the COPD patients with regard to weakness and fatigue.
Weakness and fatigue are general terms, used to broadly 
indicate deficiencies in neuromuscular function. The term 
“weakness” has been defined as a persistent disturbance in 
force-generating capacity while “fatigue” is a loss in the 
capability to generate an expected force when provoked by 
repetitive contractions.64 It is important to emphasize that dur-
ing voluntary effort, the origin of weakness and fatigue may 
be central (neural) as a result of an inability to fully activate 
the motoneuron pool, both within and between synergistic 
muscles, peripheral (muscle) as a consequence of intrinsic 
abnormalities in the muscle fiber itself or a combination of 
both central and peripheral. At present, the locus of weakness 
and fatigue in COPD has been given little attention.
The characterization of weakness and fatigue may also be 
task-dependent, influenced by the specific demands imposed 
on the neural and muscular components. Tasks may be gener-
ally subdivided into those which are conducted at constant 
muscle length (isometric) and into those in which movement 
or velocity is involved (dynamic). From a muscle perspective, 
the intrinsic properties of the excitation and contraction 
processes in the cell represent the primary determinants of 
mechanical behavior.
Given the abnormalities observed in the two COPD 
patients included in this paper several effects on weak-
ness and fatigue should occur. The shift in the fiber types 
towards a greater proportion of type II fibers accompanied 
Table 5 A comparison between healthy controls and two patients 
with chronic obstructive pulmonary disease on selected proper-
ties of the sarcoplasmic reticulum and the Na+-K+-ATPase in tissue 
obtained from the vastus lateralis muscle
CON COPD #1 COPD #2
Sr
Ca2+-ATPase
vmax (µmol.g pro-1.min-1) 175 ± 13 147 NA
Ca50 (nM) 883 ± 51 1445 NA
nH 2.17 ± 0.05 153 NA
Lonophore ratio 3.3 ± 1.3 3.7 NA
Ca2+-uptake (µmol.g pro-1.min-1) 5.04 ± 1.2 4.32 NA
Coupling ratio 0.029 ± 0.01 0.029 NA
Ca2+-release (µmol.g pro-1.min-1)
Phase 1 20 ± 0.26 16.4 NA
Phase 2 5.39 ± 1.7 5.11 NA
Na+-K+-ATPase
βmax (pmol.g wet wt-1) 283 ± 36 228 336
vmax (nmol.mg pro-1.h -1) 93.1 ± 8.0 61.9 85.9
Notes: values are x SE ± . For CON, n = 4 for Na+-K+-ATPase and n = 2 for Sr.
Abbreviations: CON, control; COPD #1 and COPD #2, two chronic obstructive 
pulmonary disease patients; Sr, sarcoplasmic reticulum;    vmax, maximal catalytic activity; 
Ca50, Ca2+ concentration needed to elicit 50% maximal Ca2+-ATPase activity; nH, Hill 
coefficient, as determined from Hill plots using the relationship between free Ca2+ 
concentration and Ca2+-ATPase activity and the section of the curve that corresponds 
to 10%–90% maximal Ca2+-ATPase activity; lonophore ratio, ratio between vmax 
determined with and without the Ca2+-ionophore, A-23187; Coupling ratio, ratio of 
Ca2+-uptake to  vmax; Ca2+-release, calculated as a fast (Phase 1) and slow phase (Phase 2); 
βmax, maximal enzyme content as measured by the[3H] oubain binding procedure;    vmax, 
maximal catalytic activity as measured by the 3-O-methyl fluorescein phosphatase 
(3-O-MFPase) assay; NA, not available.International Journal of General Medicine 2009:2 240
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by a reduction in type I fibers, would be expected to promote 
tasks performed at high velocity as a result of the increase in 
the fast myosin heavy chain isoforms.10 However, the muscle 
atrophy observed would compromise force-generating capac-
ity both during isometric and dynamic contractions.10 The 
resulting weakness would in itself promote a more rapid 
fatigue compared to healthy individuals during repetitive 
tasks performed at a given absolute requirement.
To preserve contractile function during submaximal 
repetitive activity, the muscle cell must be able to respond to 
each of the neural impulses by generating an action potential 
and conducting the action potential on the surface of the 
fiber and into the interior of the fiber by the sarcolemma amd 
t-tubule, respectively. During submaximal contractions, the 
impulse frequency could be in the range of 10–20 Hz. The 
integrity of the action potentials depends on re-establishing 
the resting membrane potential between each excitation, 
a condition which depends on the active transport of Na+ 
and K+, and the restoration of the transmembrane gradients 
for each cation. This function is, in large part, determined by 
the catalytic activity of the Na+-K+-ATPase.58 It is clear that 
in COPD #1, the maximal catalytic activity was depressed, 
a condition that could result in an inability to generate repeti-
tive action potentials. If such was the case, communication 
with the SR would be compromised, Ca2+-release reduced, 
Ca2+-induced myofibrillar activation disrupted and fatigue 
accelerated.61
Intrinsic alterations at the level of the SR itself may 
also alter the mechanical response to sustained activity. For 
COPD #1, on whom we have been able to measure several 
SR properties, it is clear that abnormalities exist, particularly 
with the Ca2+-uptake function of the SR. The reduction in 
Ca2+-uptake observed in this patient would be expected to 
promote reductions in the relaxation rate in the fiber after 
a contraction, which could, depending on the activation 
level, result in a reduction in Ca2+-release. Reductions in 
Ca2+-release, leading to a depression in the concentration of 
cytosolic-free Ca2+, have been identified as a primary cause 
of fatigue during submaximal activity characterized by a rela-
tively low frequency of activation (low frequency fatigue).64 
In addition to the reduction in Ca2+-uptake observed in this 
patient, abnormalities were also found in the regulatory 
behavior of the enzyme. The loss of Ca2+-sensitivity, as an 
example, unless compensated for, would have important 
implications to the cytosolic-free Ca2+ needed to achieve a 
desired Ca2+-uptake.
The alterations in energy-producing machinery within 
the cell observed in the patients may also impact on tasks 
requiring sustained activity. At rest, the energy charge in the 
cell in both patients is only modestly impaired. Consequently, 
given the relatively small requirements of a brief contraction 
on the high-energy phosphagens, it would not be expected 
that force-generating capacity would be affected. However, 
during repetitive activity, ATP must be regenerated from the 
aerobic and glycolytic metabolic pathways, the contribution 
of each depending on the demands of the task.65 A failure 
of the metabolic pathways to respond with increases in flux 
rate commensurate with increases in ATP utilization could 
result in a reduction in energy charge with accumulation 
of metabolic byproducts.12 The accumulation of selected 
metabolic byproducts, such as inorganic phosphate and ADP, 
could impair one or more of the excitation and contraction 
processes, resulting in an inability to translate a neural com-
mand in a desired force response. It is also important that 
the contribution of the aerobic pathway in ATP re-synthesis 
using carbohydrate as a substrate be optimized in order to 
increase efficiency and minimize the disruptions mediated 
with byproduct accumulation such as hydrogen ion.12 The 
apparent reduction in oxidative potential in COPD #2 could 
compromise the contribution of this pathway, necessitating 
a greater activation of glycolysis, which may be problematic 
given the reduced potential also observed in this pathway in 
this patient.
The reduced level of both the glucose and lactate 
transporters observed in COPD #2 could also impair the 
availability of the substrate, glucose, into the cell,19 which 
is needed for glycolysis, and the removal of lactate from the 
cell.20 Both are factors that could contribute to fatigue.21
As an added complication there is accumulating evidence 
to suggest that in diseases such as CHF and COPD, there 
are disturbances in ROS, either as a result of a more rapid 
production of ROS and/or a loss of antioxidant defence 
mechanisms.35 Repetitive contractile activity is known to 
increase ROS concentration and even in healthy humans 
to contribute to the inactivation that occurs to the cation 
pumps.45,58 It is possible that premature fatigue observed in 
COPD may also be related to ROS accumulation.
We emphasize that implications that we have provided 
regarding the effects of the abnormalities observed in the 
two patients are based on speculation only. However, they 
do provide a basis for beginning to predict the potential out-
comes on weakness and fatigue in COPD. The assessment 
of many more cellular properties are possible and, indeed 
necessary, in order to gain a more definitive extrapolation of 
the mechanical defects induced. The technology and protocol 
for the measurement of weakness and fatigue in response to International Journal of General Medicine 2009:2 241
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standardized tasks in COPD have been published and are 
relatively easy to administer. Much progress can be expected 
in the clinical application in this area in the future.
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